MYELOPEROXIDASE POLYMORPHISM ON ENDOTHELIAL FUNCTION AND VASCULAR COMPLIANCE

髓过氧化物酶多态性对内皮功能和血管顺应性的影响

• 批准号: 7604848
• 负责人: WILLIAM G HAYNES
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604848
• 关键词: Affect; Blood Pressure; Blood Vessels; Cholesterol; Computer Retrieval of Information on Scientific Projects Database; Condition; Dapsone; Enzymes; Functional disorder; Funding; Genes; Genetic Polymorphism; Genotype; Grant; Heart; Heart Diseases; High Blood Pressure; Hypertension; Institution; Medical; Patients; Peroxidase; Pharmaceutical Preparations; Placebos; Play; Postmenopause; Purpose; Randomized; Research; Research Personnel; Resources; Risk Factors; Role; Skin; Smoke; Source; United States Food and Drug Administration; United States National Institutes of Health; Variant; Woman; aged; day; improved; male; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine if a natural variation in a gene called "myeloperoxidase" plays a role in the abnormal functioning of blood vessels. It is known that this abnormality of blood vessels affects blood pressure and also leads to heart problems. This is a study of a particular gene, called the myeloperoxidase (MPO) gene, since medical studies have suggested that a certain change in this gene is seen more often in patients with heart disease. This is a study of blood vessel function in people having this variation in the MPO gene compared to a group that does not have the variation. This comparison will be made using a medication called dapsone. Dapsone is known to block the effect of an enzyme called "myeloperoxidase", produced by the MPO gene. Dapsone is approved by the FDA for treatment of certain skin conditions but is considered investigational for the purpose of this study. Subjects will 1) be between 18 and 45 years old and have no known risk factors for heart disaease or 2) have risk factors for heart disease such as high blood pressure, high cholesterol or have smoked more than 1 pack per day for 20 years and are a) male, aged 45-69 years, or b) postmenopausal women, less than 69 years old. Subjects will be randomly assigned to receive dapsone or placebo. The hypotheses of the study are: 1) The MPO GG genotype is associated with impaired vascular function, and 2) vascular dysfunction in subjects with GG genotype is improved by inhibiting MPO with dapsone therapy.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项研究的目的是确定“髓过氧化物酶”基因的自然变异是否在血管功能异常中发挥作用。 众所周知，这种血管异常会影响血压，还会导致心脏问题。 这是一项针对称为髓过氧化物酶（MPO）基因的特定基因的研究，因为医学研究表明该基因的某种变化在心脏病患者中更常见。 这是一项针对 MPO 基因具有这种变异的人群与没有这种变异的人群进行比较的血管功能研究。 这种比较将使用一种名为氨苯砜的药物进行。 已知氨苯砜可以阻断由 MPO 基因产生的称为“髓过氧化物酶”的酶的作用。 氨苯砜经 FDA 批准用于治疗某些皮肤病，但出于本研究的目的，被认为处于研究阶段。 受试者将 1) 年龄在 18 至 45 岁之间，没有已知的心脏病危险因素，或 2) 有心脏病危险因素，如高血压、高胆固醇或连续 20 年每天吸烟超过 1 包，并且a) 男性，年龄 45-69 岁，或 b) 绝经后女性，小于 69 岁。 受试者将被随机分配接受氨苯砜或安慰剂。 该研究的假设是：1) MPO GG 基因型与血管功能受损有关，2) GG 基因型受试者的血管功能障碍可通过氨苯砜治疗抑制 MPO 得到改善。